Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
An Observational Pregnancy Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® (Inebilizumab-cdon) During Pregnancy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Expanded Access
Expanded Access
Available
- Available: Expanded access is currently available for this investigational treatment, and patients who are not participants in the clinical study may be able to gain access to the drug, biologic, or medical device being studied.
- No longer available: Expanded access was available for this intervention previously but is not currently available and will not be available in the future.
- Temporarily not available: Expanded access is not currently available for this intervention but is expected to be available in the future.
- Approved for marketing: The intervention has been approved by the U.S. Food and Drug Administration for use by the public.
Contacts and Locations
Study Contact
Study Contact
- Name: Amgen Call Center
- Phone Number: 866-572-6436
- Email: medinfo@amgen.com
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- University of Colorado Denver
-
Principal Investigator:
- Dr. Amanda Piquet, MD
-
Contact:
- Amanda Piquet, MD
- Phone Number: 303-724-4644
- Email: AMANDA.PIQUET@CUANSCHUTZ.EDU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Provide informed consent
- Are a female of reproductive potential with a confirmed or suspected diagnosis of NMOSD
- Have been exposed to UPLIZNA during pregnancy as defined by receipt of any dose during pregnancy or within 6 months preceding conception
Note: Other Protocol Defined Inclusion/Exclusion Criteria Apply
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of newborns with Major Congenital Malformations (MCMs)
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
|
Number of newborns with Preterm birth
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
|
Number of newborns with low birth weight
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
|
Number of stillbirths
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of newborns with Minor Congenital Malformations
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
|
Number of infants with developmental milestone abnormalities
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
|
Number of infants with neurologic abnormalities
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
|
Number of infants with immune system development abnormalities
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
|
Number of Spontaneous Abortions
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
|
Number of Induced or Elective Abortions
Time Frame: Minimum of 10 years
|
Minimum of 10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: MD, Amgen
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VIB0551.P4.S4
- EUPAS105613 (Other Identifier: European Union Post Authorization Studies)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.